<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162149</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-137</org_study_id>
    <nct_id>NCT00162149</nct_id>
  </id_info>
  <brief_title>ATV/Ritonavir Nevirapine Interaction (USPAC)</brief_title>
  <official_title>Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Nevirapine on the Pharmacokinetics of Atazanavir in HIV-Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      Open-Label, multiple-dose, drug interaction study to assess the effect of nevirapine on the
      pharmacokinetics of atazanavir in HIV-infected individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady state pharmacokinetics of atazanavir/ritonavir 300/100mg &amp; 400/100mg each co-administered w/ nevirapine 200mg twice-daily w/ 2 to 3 nucleoside reverse transcriptase inhibitors relative to that of a second cohort of subj.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steady state PK of 2 atazanavir/ritonavir&amp;nevirapine regimens relative to historic data of atazanavir 400mg in HIV-inf subj;Safety &amp; tolerability of co-admin of atazanavir,ritonavir,&amp;nevirapine in the presence of 2to3 nucleoside rev. transcriptase inhibi</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment>46</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>Tablets, Oral, 200 mg, Twice daily, 3 days.</description>
    <arm_group_label>A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine + Atazanavir/Ritonavir</intervention_name>
    <description>Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.</description>
    <arm_group_label>A2</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine + Atazanavir/Ritonavir</intervention_name>
    <description>Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.</description>
    <arm_group_label>A3</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir + Ritonavir</intervention_name>
    <description>Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.</description>
    <arm_group_label>B1</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent form

          -  For Cohort 1, HIV-infected subjects receiving nevirapine 200 mg twice-daily and 2 to 3
             NRTIs for at least 6 weeks

          -  For Cohort 2, HIV-infected subjects receiving atazanavir 300 mg and ritonavir 100 mg
             once-daily and 2 to 3 NRTIs for at least 6 weeks

          -  Have had 2 measurements of plasma HIV RNA of &lt;400 copies/mL. The first test being 6 to
             16 weeks prior and the second being within 3 weeks prior to Day 1

          -  Have CD4 cell count &gt;=200 cells/mm3

          -  Body Mass Index of 18 to 35 kg/m2.

          -  Men and women, ages 18 to 55.

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Presence of a newly diagnosed HIV-related opportunistic infection or CD4 cell count
             &lt;200 cell/mm3 within the previous 6 months.

          -  Any significant acute or chronic medical illness, unless stable or controlled by a
             non-prohibited medication.

          -  History of virologic failure on an antiretroviral regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

